Verve Therapeutics
VERV
VERV was delisted on the 24th of July, 2025.
123 hedge funds and large institutions have $1.21B invested in Verve Therapeutics in 2022 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 47 increasing their positions, 29 reducing their positions, and 28 closing their positions.
683% more call options, than puts
Call options by funds: $9M | Put options by funds: $1.15M
62% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 29
0.41% more ownership
Funds ownership: 101.26% → 101.68% (+0.41%)
0% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 28
2% less funds holding
Funds holding: 125 → 123 (-2)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
42% less capital invested
Capital invested by funds: $2.08B → $1.21B (-$871M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$44.3M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$25.8M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$14.4M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$13.8M |
| 5 |
NAMA
Nikko Asset Management Americas
New York
|
+$12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$26.6M |
| 2 |
DM
Deerfield Management
New York
|
-$25.8M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$25.2M |
| 4 |
CC
Casdin Capital
New York
|
-$23.5M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.3M |
VERV Hedge Fund Activity: Q4 2022 in Review
123 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q4 2022, worth a combined $1.21B — down 42% from $2.08B a quarter earlier.
Fund positioning in VERV was balanced in Q4 2022: 28 funds opened new positions, 28 closed out, 47 added to existing stakes and 29 trimmed.
The largest buyer was State Street, adding an estimated $44.3M. The largest seller was Deep Track Capital, exiting entirely with an estimated $26.6M sold.
- 123 institutional investors held Verve Therapeutics (VERV) as of Q4 2022, down from 125 in Q3 2022.
- Funds reported $1.21B of Verve Therapeutics stock for Q4 2022, down 42% quarter-over-quarter.
- 28 funds opened new Verve Therapeutics positions in Q4 2022 and 28 closed out, a net change of 0 holders.
- The largest Verve Therapeutics buyer in Q4 2022 was State Street, an estimated $44.3M added.
- The largest Verve Therapeutics seller in Q4 2022 was Deep Track Capital, an estimated $26.6M sold.
Based on aggregated 13F filings for Q4 2022.